Catalent Inc
NYSE:CTLT
Intrinsic Value
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer healt... [ Read More ]
The intrinsic value of one CTLT stock under the Base Case scenario is 56.13 USD. Compared to the current market price of 55.48 USD, Catalent Inc is Undervalued by 1%.
Valuation Backtest
Catalent Inc
Run backtest to discover the historical profit from buying and selling CTLT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Catalent Inc
Current Assets | 2.6B |
Cash & Short-Term Investments | 229m |
Receivables | 1.3B |
Other Current Assets | 1B |
Non-Current Assets | 7.4B |
PP&E | 3.8B |
Intangibles | 3.3B |
Other Non-Current Assets | 379m |
Current Liabilities | 1B |
Accounts Payable | 407m |
Accrued Liabilities | 341m |
Other Current Liabilities | 288m |
Non-Current Liabilities | 5.3B |
Long-Term Debt | 5B |
Other Non-Current Liabilities | 306m |
Earnings Waterfall
Catalent Inc
Revenue
|
4.1B
USD
|
Cost of Revenue
|
-3.4B
USD
|
Gross Profit
|
735m
USD
|
Operating Expenses
|
-1B
USD
|
Operating Income
|
-272m
USD
|
Other Expenses
|
-1B
USD
|
Net Income
|
-1.3B
USD
|
Free Cash Flow Analysis
Catalent Inc
What is Free Cash Flow?
CTLT Profitability Score
Profitability Due Diligence
Catalent Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Catalent Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
CTLT Solvency Score
Solvency Due Diligence
Catalent Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Catalent Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTLT Price Targets Summary
Catalent Inc
According to Wall Street analysts, the average 1-year price target for CTLT is 57.83 USD with a low forecast of 42.42 USD and a high forecast of 66.68 USD.
Ownership
CTLT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CTLT Price
Catalent Inc
Average Annual Return | 17.08% |
Standard Deviation of Annual Returns | 60.59% |
Max Drawdown | -78% |
Market Capitalization | 10B USD |
Shares Outstanding | 180 738 000 |
Percentage of Shares Shorted | 5.25% |
CTLT News
Last Important Events
Catalent Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Catalent Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.
Contact
IPO
Employees
Officers
The intrinsic value of one CTLT stock under the Base Case scenario is 56.13 USD.
Compared to the current market price of 55.48 USD, Catalent Inc is Undervalued by 1%.